Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF11167 for persistent prominent negative symptoms in schizophrenia
2018-001581-42Phase 2Terminated
- Sponsor
- Lundbeck
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Lu AF11167 in schizophrenia (3 arms), sponsored by Lundbeck. Primary endpoint: Change in BNSS total score. Started Oct 2018; status: terminated.
02
Drugs
Lu AF11167
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2018-001581-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001581-42.